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A B S T R A C T
Background: The eﬀect of duration of illness and antipsychotic medication on the volumes of subcortical
structures in schizophrenia is inconsistent among previous reports. We implemented a large sample analysis
utilizing clinical data from 11 institutions in a previous meta-analysis.
Methods: Imaging and clinical data of 778 schizophrenia subjects were taken from a prospective meta-analysis
conducted by the COCORO consortium in Japan. The eﬀect of duration of illness and daily dose and type of
antipsychotics were assessed using the linear mixed eﬀect model where the volumes of subcortical structures
computed by FreeSurfer were used as a dependent variable and age, sex, duration of illness, daily dose of
antipsychotics and intracranial volume were used as independent variables, and the type of protocol was in-
corporated as a random eﬀect for intercept. The statistical signiﬁcance of ﬁxed-eﬀect of dependent variable was
assessed.
Results: Daily dose of antipsychotics was positively associated with left globus pallidus volume and negatively
associated with right hippocampus. It was also positively associated with laterality index of globus pallidus.
Duration of illness was positively associated with bilateral globus pallidus volumes. Type of antipsychotics did
not have any eﬀect on the subcortical volumes.
Discussion: A large sample size, uniform data collection methodology and robust statistical analysis are strengths
of the current study. This result suggests that we need special attention to discuss about relationship between
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T
subcortical regional brain volumes and pathophysiology of schizophrenia because regional brain volumes may
be aﬀected by antipsychotic medication.
1. Introduction
Numerous systematic reviews and meta-analyses of magnetic re-
sonance imaging (MRI) studies have shown the various regional volume
changes in patients with schizophrenia (Fusar-Poli et al., 2013; Haijma
et al., 2013; Ho et al., 2011; Honea et al., 2005; Huhtaniska et al.,
2017b; Hulshoﬀ Pol and Kahn, 2008; Moncrieﬀ and Leo, 2010; Navari
and Dazzan, 2009; Olabi et al., 2011; Steen et al., 2006; Torres et al.,
2013; Vita et al., 2012; Woods et al., 2005; Wright et al., 2000).
However, a meta-review of these review reports pointed out that the
quality of evidence for morphological changes in subjects with schi-
zophrenia is moderate due to unreliable data and inconsistent review
methodology (Shepherd et al., 2012). In addition, not all collected data
was fully explored in retrospective meta-analyses because of metho-
dological inconsistency among the included studies, and the number of
studies or subjects was often small in sub-group analyses such as those
conducted on a particular anatomical region (Haijma et al., 2013; van
Erp et al., 2016; Wright et al., 2000).
Prospective meta-analysis, which is the analysis of brain scans
worldwide using standardized method, is a new attempt in this ﬁeld,
ﬁrst adopted by ENIGMA (Enhancing Neuro Imaging Genetics by Meta-
Analysis) schizophrenia Working Group (van Erp et al., 2016). In this
type of study, brain scans are analyzed using standardized methods
with automated imaging analysis software at each site, and summary
statistics computed are collected. The large number of subjects in the
analysis for a particular anatomical region, homogeneity of imaging
and statistical analysis and quality assurance are particular strengths of
this type of study. The ﬁrst report by the ENIGMA consortium revealed
that schizophrenia patients showed smaller hippocampus, amygdala,
thalamus, accumbens, and intracranial volume (ICV), as well as larger
globus pallidus and lateral ventricle. These ﬁndings were perfectly re-
plicated by the second prospective meta-analysis conducted by Japa-
nese COCORO (Cognitive Genetic Collaborative Research Organization)
consortium, where the rank order and magnitude of the eﬀect sizes for
subcortical volumetric changes in schizophrenia was identical to the
original (Okada et al., 2016). In addition, the study in Japan revealed
schizophrenia speciﬁc leftward asymmetry for globus pallidus volume.
One major limitation of the study in Japan is that it did not take into
account the eﬀects of duration of illness and antipsychotic treatment
(Okada et al., 2016). The original ENIGMA study showed that duration
of illness was positively associated with putamen and globus pallidus
group contrast eﬀect sizes, and dose of antipsychotics and proportion of
second generation antipsychotics were positively associated with lateral
ventricle volume group contrast eﬀect size (van Erp et al., 2016).
However, their moderator analysis was implemented using meta-re-
gression method where speciﬁc summary statistics of each sites were
used to examine the eﬀect of mediators such as other meta-analyses.
The ﬁndings of previous meta-analyses were inconsistent on the eﬀects
of duration of illness and antipsychotic medication on the volume
changes (Shepherd et al., 2012), and a new approach adhering to a
higher degree of precision is warranted.
In this study, we gathered the clinical data of all subjects in previous
prospective meta-analysis and analyzed it using uniform, robust sta-
tistical method. In this type of study, it is essential to obtain the consent
of transfer of data from all subjects who are visiting in diﬀerent in-
stitutions (van Erp et al., 2016), and close cooperation within the CO-
CORO network made it possible. Our main objective is to examine
whether the eﬀect of duration of illness, total daily dose and type of
antipsychotics on the brain volume changes would become evident with
this new methodology.
2. Materials and methods
2.1. Sample subjects and imaging
Imaging data of 883 schizophrenia subjects was taken from the
prospective meta-analysis conducted by COCORO consortium in Japan.
Detailed information on subjects and imaging protocols was given in
our previous report (Okada et al., 2016). Brieﬂy, T1-weighted magnetic
resonance images of 1117 subjects with schizophrenia from 11 sites (26
protocols) were gathered, visually checked and processed with Free-
Surfer software version 5.3 (http://surfer.nmr.mgh.harvard.edu). After
the quality control and exclusion of the subjects from the protocol with
small sample size (lower than 50 total subjects or lower than 10 sub-
jects in either diagnostic group), images of subcortical segmentation
and regional volumes (for bilateral lateral ventricles, thalamus,
Table 1
Characteristics of the included protocols for analysis of the eﬀects of duration of illness and daily dose of antipsychotics.
Protocol name Age Duration of illnessa Daily dose of antipsychoticsb Vendor MFS
N Male Female Mean s.d. Mean s.d. Median Mean s.d. Median
Osaka A 123 71 52 35.9 12.2 11.8 9.7 10.0 595.7 505.4 425.0 GE 1.5 T
Tokyo A 100 57 43 33.4 9.5 10.5 8 9.5 814.1 610.4 626.0 GE 1.5 T
Osaka B 68 33 35 33.2 11.6 10.9 8.9 8.0 839.5 683 750.0 GE 3.0 T
Toyama A 111 58 53 26.6 6.3 4.1 5.1 2.0 550 440.7 400.0 Siemens 1.5 T
Kyoto 83 44 39 36.2 9.1 13 8.6 12.0 559.1 375.9 450.0 Siemens 3.0 T
Hokkaido 92 32 60 35.2 12 8.6 9.7 4.9 749.3 582.6 600.0 Siemens 1.5 T
Tokyo B 42 27 15 30.7 8.8 8.9 7.1 6.1 870.8 737.1 625.0 GE 3.0 T
Nagoya A 43 26 17 43.6 10.6 19.8 11.4 18.0 610.3 439.3 600.0 Siemens 3.0 T
Kyushu A 25 7 18 38.5 8.1 13.4 7.8 11.0 673.5 410.2 600.0 Philips 3.0 T
Kanazawa-med 34 14 20 35.9 9.5 10.2 9.2 7.5 519.1 463.4 376.5 Siemens 3.0 T
UOEH 11 4 7 29.4 14.4 0.7 1 0.0 239.7 164.8 200.0 GE 3.0 T
Yaesu A 11 6 5 38.4 4.2 10.6 6.4 12.0 765 479.3 750.0 Philips 3.0 T
Tokyo C 11 5 6 31.5 14.3 7.5 8.9 3.8 511.2 456.4 400.0 GE 3.0 T
Kyushu B 24 13 11 35.1 11.3 8.3 7 5.0 576.9 491.5 387.5 Philips 3.0 T
Total 778 397 381 34.5 10.1 9.9 7.8 8.0 633.9 488.6 504.5
Abbreviations: MFS, magnetic ﬁeld strength.
a Years.
b Chlorpromazine equivalent daily dose of antipsychotics at the time of scanning.
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caudate, putamen, globus pallidus, hippocampus, amygdala, ac-
cumbens and ICV) of 884 subjects from 15 protocols were used in the
previous study. Among these 884 subjects, one subject withdrew their
consent during preparation of current study. The remaining 883 sub-
jects were included.
2.2. Sample demographics
Of 6 sample demographics (age, sex, ICV, duration of illness, total
daily dose of antipsychotics, type of antipsychotics) that we used as
moderators in the current analysis, age, sex and ICV information had
been obtained in the previous study (Okada et al., 2016). Duration of
illness (years) and antipsychotic medication (name and dose of all an-
tipsychotics that were prescribed at the time of scanning) were checked
for the current study at each site. The chlorpromazine equivalents of
daily dose of all prescribed antipsychotics at the time of scanning were
computed (daily dose of antipsychotics) (Inada and Inagaki, 2015)
(Supplementary Table 1). In each analysis, among potential candidate
protocols, protocols with lower than 5 participants in the groups to be
compared were excluded to minimize the unfavorable eﬀects of very
small groups.
From 883 subjects with schizophrenia, 14 were excluded due to the
lack of duration of illness information, 1 was excluded due to the lack of
prescription information, 33 were excluded due to the lack of both, and
57 subjects were excluded because no antipsychotics were prescribed.
The result was, 778 subjects with schizophrenia from 14 protocols (11
institutions) were included in the analysis of the eﬀect of duration of
illness and daily dose of antipsychotic on the volumes of subcortical
structures (Table 1). In the analysis of the eﬀect of type of anti-
psychotics, we compared subjects who were prescribed atypical anti-
psychotics only with the subjects who were prescribed typical anti-
psychotics only (Jorgensen et al., 2016). In this process, 195 subjects
who were prescribed both typical and atypical antipsychotics were
excluded, and 8 protocols with 209 subjects were excluded as subjects
prescribed typical antipsychotics were lower than 5 in these protocols.
As a result, 389 subjects from 6 protocols (5 institutions) were included
in the second analysis (Supplementary Table 2).
2.3. Analysis of eﬀect of moderators
Following the previous ENIGMA study, we adopted a general linear
model to examine the eﬀect of moderators. In addition, since the eﬀect
of brain volume caused by the scanner characteristics could be asso-
ciated with the results (van Erp et al., 2014), we added the eﬀect of
protocol to moderators. As we were not interested in the size of the
eﬀect of protocols, and because 14 protocols was quite a large number
for our total number of subjects, we incorporated the eﬀect of protocol
as random eﬀect, not as ﬁxed eﬀect (Michael, 2015). We selected the
linear mixed-eﬀects model (LMM) where the volumes of subcortical
structures were used as a dependent variable and age, sex, duration of
illness, chlorpromazine equivalent daily dose of antipsychotics and ICV
were used as independent variables, and type of protocol was in-
corporated as a random eﬀect for intercept only (see supplementary
information for details of model selection).
All dependent and independent variables were scaled before esti-
mation. The statistical signiﬁcance of the ﬁxed-eﬀect of duration of
illness, daily dose of antipsychotics, and type of antipsychotics was
assessed in t-test. The Satterthwaite approximated degree of freedom
was obtained and a parameter-speciﬁc p value was calculated for each
dependent variable (Satterthwaite, 1946). The signiﬁcant level was set
at 0.05, and Bonferroni correction was applied to the statistical results
to reduce type-I errors generated by multiple comparisons (Okada et al.,
2016). Further, we conﬁrmed the result of t-test using parametric
bootstrapping test to compensate for the asymptotic assumption of t-test
for null distribution of parameter estimates in mixed eﬀect model
(Douglas Bates et al., 2015). In parametric bootstrapping test, the re-
sampling number was set to 1000 and beta coeﬃcients of moderators
were estimated each time, and 95% conﬁdence interval of beta coeﬃ-
cients was obtained from the null distribution (Douglas Bates et al.,
2015). All LMM analyses were conducted using lmer function in the
lme4 package (Douglas Bates et al., 2015) running on R statistics 3.1.2
(https://www.r-project.org). The coef function of lmerTest package was
used to obtain the Satterthwaite approximated degree of freedom
(Douglas Bates et al., 2015). The bootMer function of lme4 package was
used to implement parametric bootstrapping in mixed linear model
(Douglas Bates et al., 2015).
Fig. 1. Beta value for duration of disease ± standard er-
rors for standardized regional volume.
Beta value was calculated from mixed eﬀect model where
the volumes of subcortical structures, lateral ventricles and
ICV were used as a dependent variable and age, sex,
duration of illness, chlorpromazine equivalent daily dose of
antipsychotics and ICV were used as independent variables,
and type of protocol was incorporated as a random eﬀect.
accumb, accumbens; amyg, amygdala; caud, caudate;
hippo, hippocampus; ICV, intracranial volume; L, left;
LatVent, lateral ventricle; pal, pallidum; put, putamen; R,
right; thal, thalamus.
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2.4. The eﬀect of duration of illness and antipsychotic medication on
laterality index (LI) of subcortical regional volumes
As we found the schizophrenia speciﬁc leftward asymmetry of
globus pallidus volume in our previous study (Okada et al., 2016), we
examined the eﬀect of duration of illness, antipsychotic medication,
type of antipsychotics, on the laterality of globus pallidus volumes.
Laterality index (LI) deﬁned as the ratio [(left− right) / (left + right)]
can range from −1 to 1 and a positive LI indicates a leftward asym-
metry (Okada et al., 2016). The statistical signiﬁcance of ﬁxed-eﬀects of
duration of illness, daily dose of antipsychotics and type of anti-
psychotics was assessed using the same procedure as volume analysis.
As LI is the ratio, we did not include ICV volume as an independent
variable.
2.5. Comparison of medicated subjects with drug free subjects
To examine the regional brain volume of drug free subjects, we have
compared their regional brain volumes with those of medicated sub-
jects. We implemented this analysis using subjects at the site where
there were 5 or more drug free subjects (Osaka A, Osaka B, Toyama A,
Hokkaido) (Supplementary Tables 3, 4). To compare drug free subjects
(n= 51) with medicated subjects (n= 394), we newly made binominal
item (1 means medicated and 0 means drug free) and used it instead of
chlorpromazine equivalent antipsychotic dose. Other than that, we
followed the method that we had used to assess the eﬀect of daily of
antipsychotics.
3. Results
3.1. Analysis of the eﬀect of duration of illness and daily dose of
antipsychotics on the volumes
Duration of illness was signiﬁcantly positively correlated with the
volumes of bilateral globus pallidus after controlling the eﬀects of age,
sex, ICV and dose of antipsychotics (left: t= 3.8, p= 1.7 × 10−4;
right: t= 4.6, p= 4.7 × 10−6) (Fig. 1, Supplementary Table 13). The
eﬀect was signiﬁcant after Bonferroni correction. This signiﬁcance was
also conﬁrmed by parametric bootstrapping. Duration of illness was
also positively correlated with right putamen volume (t= 2.5,
p= 0.01) and negatively correlated with right hippocampal volume
(t=−2.0, p= 0.05), though Bonferroni correction determined that
correlations were not signiﬁcant.
On the other hand, daily dose of antipsychotics was positively cor-
related with left globus pallidus volume (t= 3.8, p= 2.0 × 10−4) and
negatively correlated with right hippocampus volume (t=−3.0,
p= 2.4 × 10−3) after controlling the eﬀects of age, sex, ICV and
duration of illness (Fig. 2, Supplementary Table 14). The signiﬁcance
was also conﬁrmed by parametric bootstrapping. Daily dose of anti-
psychotics also showed a positive correlation with right globus pallidus
(t= 2.0, p= 0.04) and right ventricular volume (t= 2.2, p= 0.03),
and negative correlation with left hippocampus (t=−2.2, p= 0.03)
and right accumbens volumes (t=−2.2, p= 0.03), though the cor-
relations were not signiﬁcant after Bonferroni correction. The results
were not changed when we included drug free subjects. (Supplementary
Table 15).
3.2. Analysis of the eﬀect of the type of antipsychotic
Type of antipsychotics did not show any signiﬁcant association with
the volumes of subcortical regions (Supplementary Table 16, the cor-
relations were not signiﬁcant after Bonferroni correction.).
3.3. The eﬀect of duration of illness and antipsychotic medication on globus
pallidus LI
Daily dose of antipsychotics had a signiﬁcant eﬀect on globus pal-
lidus LI (t= 2.3, p= 0.02), conﬁrmed by parametric bootstrapping
(mean = 0.08, 95% conﬁdence interval = (0.01–0.15). Duration of
illness (t=−0.2, p= 0.87) and antipsychotics (t=−0.6, p= 0.58)
did not show signiﬁcant eﬀect.
Fig. 2. Beta value for daily dose of antipsychotics ±
standard errors for standardized regional volume.
Beta value was calculated from mixed eﬀect model where
the volumes of subcortical structures, lateral ventricles and
ICV were used as a dependent variable and age, sex,
duration of illness, chlorpromazine equivalent daily dose of
antipsychotics and ICV were used as independent variables,
and type of protocol was incorporated as a random eﬀect.
accumb, accumbens; amyg, amygdala; caud, caudate;
hippo, hippocampus; ICV, intracranial volume; L, left;
LatVent, lateral ventricle; pal, pallidum; put, putamen; R,
right; thal, thalamus.
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3.4. Comparison of medicated subjects with drug free subjects
The bilateral caudate were signiﬁcantly larger in medicated subjects
than drug free subjects (t= 3.6, p= 8.7 × 10−3 for left and t= 2.7,
p= 7.3 × 10−3 for right). The diﬀerence was signiﬁcant after
Bonferroni correction. Right globus pallidus was also larger in medi-
cated subjects (t= 2.0, p= 0.04), although the diﬀerence was not
signiﬁcant after Bonferroni correction. (Supplementary Table 17).
4. Discussion
In this study, we found signiﬁcant positive association between bi-
lateral globus pallidus volumes and duration of illness, and between left
globus pallidus volume and daily dose of antipsychotics. Increment of
globus pallidus volume in medicated subjects with chronic schizo-
phrenia was consistent with previous studies (Gur et al., 1998; Lang
et al., 2004; van Haren et al., 2016) and one meta-analysis (Haijma
et al., 2013). Globus pallidus showed the largest eﬀect size in com-
parison with chronic schizophrenia and control subjects in both the
ENIGMA study (van Erp et al., 2016) and the COCORO study (Okada
et al., 2016). However, the original ENIGMA study did not show sig-
niﬁcant eﬀect of daily dose of antipsychotics on the globus pallidus
volumes (van Erp et al., 2016). This suggested that our method may
have a higher sensitivity than the meta-regression analysis adopted in
the original ENIGMA study, though other factors such as the diﬀerence
in moderator, may also have inﬂuenced the result.
Because studies with antipsychotic naïve schizophrenia patients
failed to show the increase of globus pallidus volume (Gur et al., 1998;
Lang et al., 2001), it seemed that globus pallidus volume increment was
mainly induced by antipsychotics and duration of illness reﬂected the
cumulative dose of antipsychotics that each patient had taken. The
neurobiological underpinnings of basal ganglia volume increment as-
sociated with antipsychotic medication remain poorly understood. The
striatum has particularly high density of D2 receptors (Black et al.,
1997), and blockade of D2 receptor may aﬀect the cell proliferation
through modulation of the Akt signaling pathway (Beaulieu et al.,
2007). In fact, blockade of D2 receptors induce cell proliferation in
rodents has been reported, though the site was forebrain, and not
striatum (Kippin et al., 2005; Wang et al., 2004). Increment of regional
blood ﬂow was another possible mechanism of enlargement. A previous
PET study showed the increment of blood ﬂow in striatum after single
administration of haloperidol, and this eﬀect was larger than that of
olanzapine (Lahti et al., 2005). Although the meaning of regional brain
volume changes associated with antipsychotic use is not fully eluci-
dated (Huhtaniska et al., 2017b), previous study showed that larger
brain volume change was associated with lower global function (Ho
et al., 2011), more severe negative symptom (Nesvag et al., 2012), and
lower IQ (Kubota et al., 2015). These ﬁndings may indicate that we
have to care for the possible long-term undesirable eﬀect of anti-
psychotic on the brain volume and function of the subjects with schi-
zophrenia.
In contrast, we found a signiﬁcant negative association of right and
tendency of negative association of left hippocampus volume with daily
dose of antipsychotics. As the hippocampus volume reduction was also
shown in antipsychotic naïve schizophrenia subjects (Haijma et al.,
2013), antipsychotics are not the only cause of hippocampus volume
reduction. The relationship between antipsychotics and hippocampus
volume was controversial. A 6-month longitudinal study of ﬁrst episode
schizophrenia treated with quetiapine showed signiﬁcant volume loss
which was more evident in the higher dose group (Ebdrup et al., 2011).
In contrast, another longitudinal study showed that a higher dose of
atypical antipsychotics was associated with less hippocampus volume
reduction (Koolschijn et al., 2010). In the animal study, low dose of
clozapine increased a marker of DNA synthesis in the dentate gyrus, but
high dose of either clozapine or haloperidol did not produce the same
result in adult rat hippocampus (Halim et al., 2004). These studies
suggested that careful interpretation according to type and dose of
antipsychotics is necessary to examine the association between anti-
psychotic and hippocampus volume.
The. LI of globus pallidus showed marginally signiﬁcant association
with daily dose of antipsychotics. Although few studies have examined
the association of antipsychotic treatment and LI of globus pallidus, our
result corresponded with the previous study by Gur and colleagues
which showed that LI was higher in previously medicated schizo-
phrenia subjects than in never medicated subjects or healthy compar-
ison (Gur et al., 1998).
Current study did not ﬁnd any eﬀect of type of antipsychotics on the
subcortical volumes. Previous studies showed that prescription of ty-
pical antipsychotics was associated with increment of caudate volume
(Keshavan et al., 1994) and switching from typical antipsychotic to
olanzapine (Lang et al., 2004) or clozapine (Frazier et al., 1996) reduces
volume of caudate and globus pallidus. On the other hand, one meta-
analysis with large sample size (Haijma et al., 2013) and original EN-
IGMA study did not ﬁnd association between antipsychotics and sub-
cortical structural volumes, as current results. Jorgensen and colleagues
has examined the relationship between basal ganglia volume and type
of antipsychotics and found that subjects with typical antipsychotics
had larger putamen than those with atypical antipsychotic but this ef-
fect was speciﬁcally attributed to clozapine (Jorgensen et al., 2016). In
this report subjects with clozapine has smaller putamen than control
subjects and subjects with olanzapine. Taken together, drug type of
antipsychotics may have eﬀect on subcortical volumes but dividing all
antipsychotics into typical and atypical antipsychotics may be too
simple (Jorgensen et al., 2016). It is future consideration to examine the
diﬀerence of eﬀects on brain volumes among antipsychotics according
to more detailed features like the strength of D2 blockade.
About the comparison of drug free subjects with medicated subjects,
the bilateral caudate were signiﬁcantly larger in medicated subjects.
One previous meta-analysis showed that drug free subjects showed
signiﬁcantly smaller caudate than control. (Haijma et al., 2013) Be-
cause medication had positive eﬀect on the volume of basal ganglia
(caudate, putamen, globus pallidum), small volume of drug free sub-
jects might be a reason why diﬀerence in caudate between drug free
subjects and medicated subjects was more notable than in putamen or
in globus pallidum. However, the number of drug free subjects was
small and ﬁndings should be interpreted with caution.
There are several limitations in our study. Firstly, although we used
the daily dose of antipsychotics at the time of scanning as a moderator,
the lack of data on medication history is an important limitation.
Andreasen and colleagues argued for the importance of use of cumu-
lative antipsychotic exposure to assess the eﬀect of antipsychotic on
brain volume (Andreasen et al., 2010). Although prospective meta-
analysis is very eﬀective way for imaging study with large sample, it is
inevitably cross-sectional, and as a result, cumulative dose is not
available. In our opinion, using the daily dose of antipsychotics at the
date of scan of each subject could be the second-best choice if we would
like to examine the eﬀect of antipsychotic on brain volume using large
sample. The concordance of the current results with meta-analysis of
longitudinal studies most of which examined the eﬀect of cumulative
dose (Huhtaniska et al., 2017b) might support our idea. In this meta-
analysis, higher antipsychotic dose was associated with higher basal
ganglia volume. Secondly, although we assessed the eﬀect of 6 mod-
erators on subcortical volumes, other cofounding factors can inﬂuence
regional brain volume, including medication other than antipsychotics
(van Erp et al., 2016). For example, cumulative dose of benzodiazepine
was shown to have negative eﬀect on the caudate volume (Huhtaniska
et al., 2017a). Lack of assessment of illness severity is the third lim-
itation of our study. However, the original ENIGMA study found the
association of negative symptom severity with lateral ventricular vo-
lume, but not with subcortical regional volumes (van Erp et al., 2016).
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5. Conclusions
In conclusion, we have demonstrated that daily dose of anti-
psychotics was positively associated with left globus pallidus volume,
and negatively associated with right hippocampus volume, and that
duration of illness was positively associated with bilateral globus pal-
lidus volumes. A large sample size, uniform data collection metho-
dology and robust statistical analysis are strengths of the current study.
This result suggests that we need special attention to discuss about
relationship between subcortical regional brain volumes and patho-
physiology of schizophrenia because regional brain volumes may be
aﬀected by antipsychotic medication.
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